GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Debt-to-Revenue

NewAmsterdam Pharma Co NV (FRA:KH6) Debt-to-Revenue : 0.01 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

NewAmsterdam Pharma Co NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.06 Mil. NewAmsterdam Pharma Co NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.00 Mil. NewAmsterdam Pharma Co NV's annualized Revenue for the quarter that ended in Dec. 2023 was €6.78 Mil. NewAmsterdam Pharma Co NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.01.


NewAmsterdam Pharma Co NV Debt-to-Revenue Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV Debt-to-Revenue Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
N/A N/A - -

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial N/A - 0.01 0.01 0.01

Competitive Comparison of NewAmsterdam Pharma Co NV's Debt-to-Revenue

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NewAmsterdam Pharma Co NV's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's Debt-to-Revenue falls into.



NewAmsterdam Pharma Co NV Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

NewAmsterdam Pharma Co NV's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.055 + 0) / 12.921
=0.00

NewAmsterdam Pharma Co NV's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.055 + 0) / 6.784
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


NewAmsterdam Pharma Co NV Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (FRA:KH6) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (FRA:KH6) Headlines

No Headlines